Expression and clinical significance of CXCL8 in cervical cancer

1.Bioinformatics analysis based on online databasesBy integrating the data resources of the Cancer Genome Atlas (TCGA) and GTEx databases, we used the biomedical data analysis tool SangerBox to explore in depth the differential expression of the CXCL8 gene in a variety of cancerous tissues and normal tissues. Further, with the help of the GEPIA online database, we analyzed the expression differences of the CXCL8 gene in cervical cancer and its paracancerous tissues in detail. In order to comprehensively assess the impact of CXCL8 gene expression on cancer prognosis, we performed an in-depth analysis of the relationship between the CXCL8 gene and pan-cancer prognosis using overall survival (OS) as an assessment index. Specifically, in cervical cancer (CESC) patients, we further explored the association between CXCL8 gene expression and prognosis. When determining the cutoff value, we strictly based it on the principle of sample size proportion to ensure the rationality and statistical validity of grouping, i.e., the minimum grouping sample size proportion should not be lower than 25%, and the maximum should not be more than 75%. Based on this scientific grouping, we divided the patients into two groups of high and low expression and utilized the survival package and survfit function of R software to conduct a detailed comparative analysis of the prognosis of the two groups.2.Clinical validationA total of 94 patients with cervical squamous cell carcinoma admitted to the First Affiliated Hospital of Xinjiang Medical University between January 2017 and December 2021 were included in this study, all of whom had complete clinical data and pathological tissue samples. The pathological tissues of the above patients were routinely prepared into immunological sections for immunohistochemistry experiments to analyze the expression of CXCL8 and its clinical significance in this population. Statistical analysis was performed using SPSS software. Measurement data were statistically described by mean±standard deviation, count data were statistically described by relative composition ratio/rate, rank data were statistically analyzed using the rank-sum test, and the relationship between the protein expression of CXCL8 and the clinical data of patients with cervical cancer was analyzed using the chi-square or Fisher's exact test. p<0.05 was taken to mean that the difference was statistically significant.

1. 基于在线数据库的生物信息学分析
整合癌症基因组图谱（Cancer Genome Atlas, TCGA）与基因型组织表达数据库（Genotype-Tissue Expression, GTEx）的数据资源，本研究采用生物医学数据分析工具SangerBox，深入探究CXCL8基因在多种癌组织与正常组织中的差异表达情况。随后，借助基因表达谱交互分析（Gene Expression Profiling Interactive Analysis, GEPIA）在线数据库，本研究进一步详细分析了CXCL8基因在宫颈癌及其癌旁组织中的表达差异。为全面评估CXCL8基因表达对癌症预后的影响，本研究以总生存期（Overall Survival, OS）作为评估指标，深入分析CXCL8基因与泛癌预后的关联关系。具体而言，针对宫颈鳞状细胞癌（Cervical Squamous Cell Carcinoma, CESC）患者，本研究进一步探究了CXCL8基因表达与预后的关联。在确定截断值时，本研究严格遵循样本量占比原则，以确保分组的合理性与统计学有效性，即分组的最小样本占比不得低于25%，最大样本占比不得超过75%。基于此科学分组方案，本研究将患者分为高表达组与低表达组，并借助R软件的survival包及survfit函数，对两组患者的预后情况展开详细对比分析。
2. 临床验证
本研究纳入2017年1月至2021年12月期间于新疆医科大学第一附属医院收治的94例宫颈鳞状细胞癌患者，所有患者均具备完整的临床资料与病理组织样本。研究人员将上述患者的病理组织常规制备为免疫组化切片，开展免疫组织化学实验，以分析CXCL8在该队列中的表达情况及其临床意义。本研究采用SPSS软件进行统计学分析：计量资料以均值±标准差进行统计描述，计数资料以相对构成比/率进行统计描述，等级资料采用秩和检验进行统计学分析；采用卡方检验或Fisher确切概率法分析CXCL8蛋白表达与宫颈癌患者临床资料之间的关联关系。以p<0.05作为差异具有统计学意义的判定标准。